Home › Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
 

Keywords :   


Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen

2014-08-26 16:20:33| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Agreement to Combine Mercks Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizers crizotinib (XALKORI) in Clinical Trial WHITEHOUSE STATION, N.J. Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizers crizotinib (XALKORI) with Mercks investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Language: English read more

Tags: study combination evaluating collaborate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »